All In Biotech

Drug Trial Radar · NCT07222670

A Study Assessing Safety, Tolerability, and Efficacy of INNA-051 in Preventing Respiratory Illness Due to Viral Infections in Healthy Adults 18 to 45 Years of Age

A Randomized, Double-Blind, Two-Part, Placebo-Controlled, Multicenter, Phase 2a Study to Evaluate Safety, Tolerability, and Efficacy of INNA-051 as Prophylaxis for Respiratory Tract Illness in Healthy Adults 18 to 45 Years of Age Who Are at Risk for Viral Respiratory Infections

Last checked: Nov 20, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 1,100 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,100

Planned (sponsor's estimate)

Start

Dec 4, 2025

Primary completion

Mar 12, 2027

Study completion Apr 9, 2027

Sponsor

Lead sponsor
ENA Respiratory Pty LtdIndustry
Sponsor type
Industry
First posted
Oct 30, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Acute upper and lower respiratory infections are a major public health problem and a leading cause of morbidity and mortality worldwide. The purpose of this trial is to assess the safety of the investigational agent INNA-051, given intranasally, and its potential effectiveness in reducing the occurrence, severity, and/or the duration of illness resulting from respiratory virus infections. The trial will enroll generally healthy adults (age 18 - 45 years) who are at risk for exposure to viral respiratory infection, for example, due to living conditions or occupation. Participants will be treated with INNA-051 or placebo once weekly for 4 weeks (Part A) or 12 weeks (Part B) during the respiratory virus season.

Conditions

  • Viral Respiratory Infection
  • Viral Respiratory Illnesses

Interventions

  • INNA-051Drug

    powder nasal spray.

  • PlaceboOther

    powder nasal spray.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A - Number of Participants with Treatment-emergent Adverse Events (TEAEs)Time frame: Up to 8 weeks
  2. Part A - Percentage of Participants with TEAEsTime frame: Up to 8 weeks
  3. Part A - Number of participants with Serious Adverse Events (SAEs)Time frame: Up to 8 weeks
  4. Part A - Percentage of Participants with SAEsTime frame: Up to 8 weeks
  5. Part A - Number of Participants with Nasal Irritancy Questionnaire Symptoms (iTNSS Questionnaire)Time frame: Up to 4 weeks
  6. Part A - Percentage of Participants with Nasal Irritancy Questionnaire Symptoms (iTNSS Questionnaire)Time frame: Up to 4 weeks
  7. Part A - Change in White Blood Cell Count from BaselineTime frame: Baseline up to 4 weeks
  8. Part A - Change in Platelet Count from BaselineTime frame: Baseline up to 4 weeks
  9. Part A - Change in Hemoglobin from BaselineTime frame: Baseline up to 4 weeks
  10. Part A - Change in Alanine Transaminase (ALT) from BaselineTime frame: Baseline up to 4 weeks
  11. Part A - Change in Bilirubin (Total) from BaselineTime frame: Baseline up to 4 weeks
  12. Part A - Change in Bilirubin (Direct) from BaselineTime frame: Baseline up to 4 weeks
  13. Part A - Change in Alkaline Phosphatase (ALP) from BaselineTime frame: Baseline up to 4 weeks
  14. Part A - Change in Creatinine from BaselineTime frame: Baseline up to 4 weeks
  15. Part A - Change in High Sensitivity C-reactive Protein from BaselineTime frame: Baseline up to 4 weeks
  16. Part B - Number of Participants with TEAEsTime frame: Up to 16 weeks
  17. Part B - Percentage of Participants with TEAEsTime frame: Up to 16 weeks
  18. Part B - Number of Participants with SAEsTime frame: Up to 16 weeks
  19. Part B - Percentage of Participants with SAEsTime frame: Up to 16 weeks
  20. Part B - Number of Participants with Nasal Irritancy Questionnaire Symptoms (iTNSS Questionnaire)Time frame: Up to 12 weeks
  21. Part B - Percentage of Participants with Nasal Irritancy Questionnaire Symptoms (iTNSS Questionnaire)Time frame: Up to 12 weeks
  22. Part B - Change in White Blood Cell Count from BaselineTime frame: Baseline up to 12 weeks
  23. Part B - Change in Platelet Count from BaselineTime frame: Baseline up to 12 weeks
  24. Part B - Change in Hemoglobin from BaselineTime frame: Baseline up to 12 weeks
  25. Part B - Change in ALT from BaselineTime frame: Baseline up to 12 weeks
  26. Part B - Change in Bilirubin (Total) from BaselineTime frame: Baseline up to 12 weeks
  27. Part B - Change in Bilirubin (Direct) from BaselineTime frame: Baseline up to 12 weeks
  28. Part B - Change in ALP from BaselineTime frame: Baseline up to 12 weeks
  29. Part B - Change in Creatinine from BaselineTime frame: Baseline up to 12 weeks
  30. Part B - Change in High Sensitivity C-reactive Protein from BaselineTime frame: Baseline up to 12 weeks
  31. Part B - Number of Participants with Reverse Transcription Quantitative Polymerase Chain Reaction (RT-qPCR)-confirmed Symptomatic Viral Respiratory InfectionsTime frame: Up to 12 weeks
  32. Part B - Area Under the Curve (AUC) of the Total Respiratory and Systemic Symptom Scores for Participants with RT-qPCR-confirmed Symptomatic Viral Respiratory InfectionsTime frame: Up to 12 weeks

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Center for Vaccine Development and Global Health (CVD)

    Baltimore, Maryland · Recruiting

  • Naval Medical Research Command (NMRC)

    Bethesda, Maryland · Recruiting

  • University Health Center at the University of Maryland

    College Park, Maryland · Recruiting

  • Accellacare of Raleigh

    Raleigh, North Carolina · Recruiting

  • Accellacare of Piedmont HealthCare

    Statesville, North Carolina · Recruiting

  • Accellacare - Wilmington

    Wilmington, North Carolina · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.